Few new treatments in oncology and haematology have had the success that imatinib has had for chronic myeloid leukaemia (CML). This drug represents one of the best cases in the history of medicine for the development of an innovative treatment and constitutes the first example of a drug that was rationally developed to block a known oncogene and which, as monotherapy, has substantially changed the biology and clinical course of a human cancer. The 1996 paper by Druker and colleagues represents a fundamental milestone in the development of this targeted treatment and marks the beginning of what is now known as the “imatinib era”. However, the paper by Druker and colleagues also left some important aspects of the treatment undefined. They laid the foundations for further work over the following 2 years, which clarified outstanding issues and delineated the overall profile of imatinib. These achievements led to the use of imatinib in clinical trials, and its subsequent success as a targeted treatment.
Gambacorti Passerini, C. (2008). Part I: Milestones in personalised medicine - imatinib. THE LANCET ONCOLOGY, 9(6), 600 [10.1016/S1470-2045(08)70152-9].
|Citazione:||Gambacorti Passerini, C. (2008). Part I: Milestones in personalised medicine - imatinib. THE LANCET ONCOLOGY, 9(6), 600 [10.1016/S1470-2045(08)70152-9].|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Titolo:||Part I: Milestones in personalised medicine - imatinib|
|Autori:||Gambacorti Passerini, C|
|Data di pubblicazione:||giu-2008|
|Rivista:||THE LANCET ONCOLOGY|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/S1470-2045(08)70152-9|
|Appare nelle tipologie:||01 - Articolo su rivista|